<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">opa1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>OPA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>opa1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=OPA1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">421 edges</a></td>
</tr>
</table>
OPA1 (Optic Atrophy 1) is a dynamin-related GTPase localized to the mitochondrial inner membrane where it mediates inner membrane fusion and maintains cristae structure. It is essential for mitochondrial function, cristae integrity, and neuronal survival[@yu2010]. OPA1 is encoded by the nuclear genome but localizes to mitochondria, where it performs critical functions in maintaining mitochondrial morphology, energetics, and genome stability.
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">opa1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>OPA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>opa1</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=OPA1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">421 edges</a></td>
</tr>
</table>
OPA1 (Optic Atrophy 1) is a dynamin-related GTPase localized to the mitochondrial inner membrane where it mediates inner membrane fusion and maintains cristae structure. It is essential for mitochondrial function, cristae integrity, and neuronal survival[@yu2010]. OPA1 is encoded by the nuclear genome but localizes to mitochondria, where it performs critical functions in maintaining mitochondrial morphology, energetics, and genome stability.
OPA1 mutations are the most common cause of autosomal dominant optic atrophy (ADOA), a hereditary blinding disease characterized by progressive loss of retinal ganglion cells. Beyond isolated optic atrophy, OPA1 mutations can cause more complex neurological phenotypes including sensorineural hearing loss, peripheral neuropathy, and movement disorders, reflecting the essential nature of OPA1 in mitochondrial function across multiple tissue types[@ferre2015]. Recent research has revealed that OPA1 dysfunction contributes to more common neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[@carelli2015].
OPA1 is a ~100 kDa protein with multiple functional domains that execute its role in mitochondrial inner membrane fusion[@chan2020]:
N-terminal GTPase Domain: The N-terminal region contains the GTPase domain (~300 residues) that catalyzes GTP hydrolysis, providing the energy for membrane fusion. This domain shares homology with dynamin and other members of the dynamin family of GTPases. The GTPase activity is regulated by GTP/GDP binding and by interactions with other protein domains.
Middle Domain: The middle domain (~300 residues) is involved in protein-protein interactions and mediates OPA1 self-assembly. This domain allows OPA1 to form higher-order oligomers that are essential for its membrane fusion function.
GTPase Effector Domain (GED): The GED (~100 residues) regulates GTPase activity by stimulating GTP hydrolysis. It functions as a GTPase-activating protein (GAP) for OPA1, controlling the rate of GTP hydrolysis and the cycling between active and inactive states.
Coiled-Coil Domains: Multiple coiled-coil regions facilitate protein-protein interactions and oligomer formation. These domains enable OPA1 to assemble into higher-order structures at the inner membrane.
Transmembrane Region: The C-terminal transmembrane region anchors OPA1 to the mitochondrial inner membrane. This hydrophobic segment spans the membrane, positioning the GTPase domain in the intermembrane space where it can mediate fusion events.
OPA1 undergoes complex proteolytic processing that generates distinct isoforms with different functions[@stiburek2005]:
Long OPA1 (L-OPA1): The full-length protein contains both GTPase and GED domains. L-OPA1 is membrane-anchored and can mediate inner membrane fusion.
Short OOPA1 (S-OPA1): Proteolytic cleavage generates truncated isoforms that lack the GED. S-OPA1 cannot mediate fusion on its own but may regulate L-OPA1 function.
The balance between L-OPA1 and S-OPA1 is regulated by mitochondrial AAA proteases (AFG3L2 and YME1L) and OMA1, a zinc metalloprotease. This processing is sensitive to mitochondrial stress, nutrient status, and cellular energy levels.
The GTPase activity of OPA1 is essential for its membrane fusion function. Mutations affecting GTP hydrolysis cause dominant optic atrophy, demonstrating that this enzymatic activity is critical for OPA1 function in vivo. The middle domain and GED work together to regulate this activity and to mediate the self-assembly necessary for fusion.
OPA1 is the central player in mitochondrial inner membrane fusion[@chan2020]. The fusion process proceeds through several stages:
1. Tethering: OPA1 molecules on adjacent mitochondria interact through their GTPase domains, tethering the membranes together.
2. Hemifusion: The outer membranes fuse first, bringing the inner membranes into close proximity.
3. Inner Membrane Fusion: OPA1 mediates fusion of the inner membranes, completing the merging of the mitochondrial matrix.
4. Integration: The fused membranes become integrated into the continuous inner membrane network.
This fusion process maintains the mitochondrial network topology and allows for mixing of mitochondrial contents, including mitochondrial DNA (mtDNA) and proteins.
OPA1 is essential for maintaining the characteristic cristae structure of mitochondria[@pernias2018]:
Cristae Junctions: OPA1 localizes to cristae junctions, the narrow connections between cristae and the inner membrane compartment. Proper OPA1 function maintains these junctions, which are important for regulating cytochrome c release during apoptosis.
Cristae Curvature: OPA1 helps maintain the curved structure of cristae membranes, which maximizes the surface area available for ATP production.
Respiratory Chain Organization: The cristae structure organizes the respiratory chain complexes into supercomplexes, optimizing oxidative phosphorylation efficiency.
OPA1 is required for mitochondrial DNA (mtDNA) nucleoid organization and stability[@yu2010]:
Nucleoid Organization: OPA1 helps organize mtDNA into nucleoids, protein-DNA complexes that package and maintain mtDNA.
mtDNA Stability: Loss of OPA1 function leads to mtDNA depletion and the accumulation of deleted mtDNA species.
Inheritance: OPA1-mediated fusion allows mtDNA mixing and proper distribution of the mitochondrial genome.
OPA1 plays a critical role in regulating apoptosis through its effects on cristae structure[@civiero2014]:
Cytochrome c Storage: OPA1 maintains cristae structure that stores cytochrome c in a release-ready configuration.
Apoptotic Release: Upon apoptotic stimulation, OPA1 is cleaved, causing cristae remodeling and cytochrome c release.
Apoptosis Sensitivity: Loss of OPA1 function alters the sensitivity of cells to apoptotic stimuli.
Mitochondria serve as calcium buffers, and OPA1 contributes to this function:
Mitochondrial Calcium Uptake: Proper cristae structure supports calcium uniporter function.
Calcium Release: OPA1-mediated fusion allows mitochondrial calcium release during cellular signaling.
OPA1 dysfunction contributes to multiple aspects of Alzheimer's disease pathogenesis[@watson2013]:
Mitochondrial Fragmentation: OPA1 expression is reduced in AD brain, contributing to the mitochondrial fragmentation observed in AD neurons. This fragmentation impairs mitochondrial function and energy production.
Bioenergetic Deficits: Loss of OPA1 function reduces oxidative phosphorylation efficiency, contributing to the bioenergetic deficits characteristic of AD.
Cristae Disruption: OPA1-related cristae abnormalities in AD brain contribute to respiratory chain dysfunction.
Amyloid Interaction: Amyloid-beta can affect OPA1 processing and function, creating a positive feedback loop of mitochondrial dysfunction.
OPA1 deficiency sensitizes dopaminergic neurons to mitochondrial toxins and contributes to PD pathogenesis[@manzan2018]:
Mitochondrial Vulnerability: OPA1 deficiency makes dopaminergic neurons more vulnerable to mitochondrial stress.
Fragmentation: PD models show OPA1-related mitochondrial fragmentation in dopaminergic neurons.
Alpha-Synuclein Interaction: Mitochondrial dysfunction caused by OPA1 deficiency may interact with alpha-synuclein pathology.
Genetic Association: OPA1 polymorphisms have been associated with altered PD risk in some populations.
OPA1 dysfunction contributes to the mitochondrial pathology observed in ALS[@carelli2015]:
Mitochondrial Fragmentation: OPA1 aggregates have been detected in ALS motor neurons.
Energy Deficits: Loss of OPA1 function contributes to the energy deficits characteristic of ALS motor neurons.
Axonal Transport: OPA1-related mitochondrial dysfunction impairs axonal transport in motor neurons.
ADOA, caused by OPA1 mutations, is the most common inherited optic neuropathy[@delettre2000][@alexander2000]:
Epidemiology: OPA1 mutations account for approximately 60-70% of ADOA cases.
Penetrance: Disease penetrance is incomplete, with variable expressivity even within families.
Retinal Ganglion Cell Degeneration: The primary pathology is progressive degeneration of retinal ganglion cells (RGCs), leading to vision loss.
Age of Onset: Typically presents in childhood or early adulthood, but can present at any age.
Beyond isolated optic atrophy, OPA1 mutations can cause:
Sensorineural Hearing Loss: OPA1 is expressed in inner ear hair cells, and mutations can cause progressive hearing loss.
Peripheral Neuropathy: Some patients develop peripheral neuropathy with sensory and motor deficits.
Movement Disorders: Rare patients develop ataxia, spasticity, or other movement disorders.
Migraine: Some OPA1 mutation carriers experience migraine with aura.
AAV-mediated OPA1 delivery to the retina represents a promising therapeutic approach:
Preclinical Studies: AAV-OPA1 delivery in mouse models of ADOA shows rescue of retinal ganglion cell loss.
Delivery Challenges: Effective delivery to retinal ganglion cells requires optimization of AAV serotype and promoters.
Clinical Potential: Gene therapy approaches are in development for OPA1-related optic atrophy.
Several approaches to enhancing OPA1 function are being explored:
Mitochondrial Fusion Promoters: Small molecules that enhance mitochondrial fusion through OPA1 activation.
Metabolic Support: Compounds that support mitochondrial energetics, such as CoQ10 and nicotinamide riboside.
Anti-apoptotic Agents: Compounds that prevent OPA1 cleavage and cytochrome c release.
Supportive therapies that protect mitochondrial function:
CoQ10: Supports electron transport chain function.
Nicotinamide Riboside (NR): Boosts NAD+ levels and supports mitochondrial biogenesis.
Antioxidants: Protect mitochondria from oxidative stress.
The OPA1 gene is located on chromosome 3q28-q29 and encodes a protein of 1,005 amino acids. It consists of 31 exons and spans approximately 100 kb of genomic DNA. The gene is ubiquitously expressed, with highest levels in retina, brain, heart, and skeletal muscle.
Over 400 pathogenic OPA1 variants have been identified in patients with optic atrophy:
Missense Mutations: Most common, often affecting the GTPase domain or middle domain.
nonsense Mutations: Generate truncated proteins and cause haploinsufficiency.
Splice Site Mutations: Cause abnormal splicing and produce aberrant proteins.
Deletion Mutations: Rare large deletions remove parts of the gene.
The location and type of OPA1 mutation correlates with phenotype:
Isolated Optic Atrophy: Missense mutations in the GTPase domain typically cause isolated optic atrophy.
Syndromic Mutations: Nonsense or frameshift mutations that cause severe haploinsufficiency are associated with additional neurological features.
Optical Coherence Tomography (OCT): Retinal nerve fiber layer thinning in OPA1 mutation carriers.
Visual Evoked Potentials (VEP): Delayed latencies in affected individuals.
Fundus Photography: Pallor of the optic disc in affected eyes.
Serum OPA1 Levels: Reduced circulating OPA1 correlates with disease severity in some studies.
Mitochondrial Fragmentation Index: Analysis of peripheral blood mononuclear cells shows increased mitochondrial fission.
Muscle Biopsy: Mitochondrial structural abnormalities visible via electron microscopy.
Opa1 Heterozygous Mice: Opa1+/- mice exhibit mitochondrial fragmentation and age-related retinal degeneration, mimicking human ADOA.
Opa1 Conditional Knockout: Neuron-specific deletion causes progressive neurodegeneration and motor deficits.
Transgenic Models: Mouse models expressing mutant OPA1 have been developed for drug screening.
Patient Fibroblasts: Primary fibroblasts from ADOA patients show mitochondrial abnormalities.
iPSC-Derived Neurons: Patient-derived neurons allow study of disease mechanisms.
Knockdown/Overexpression Systems: siRNA and AAV systems enable functional studies.
OPA1 is a dynamin-related GTPase essential for mitochondrial inner membrane fusion and cristae structure maintenance. Mutations in OPA1 cause autosomal dominant optic atrophy, the most common inherited optic neuropathy, and contribute to more common neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. The essential role of OPA1 in mitochondrial function makes it a critical nexus linking mitochondrial dysfunction to neuronal death in multiple disease contexts.
Therapeutic strategies targeting OPA1, including gene therapy, small molecule activators, and mitochondrial protectants, hold promise for treating OPA1-related disease and potentially other neurodegenerative conditions with mitochondrial dysfunction. Continued research into OPA1 function and dysfunction will advance understanding of mitochondrial biology and develop new treatments for mitochondrial optic neuropathies and other neurodegenerative diseases.
The following diagram shows the key molecular relationships involving OPA1 Protein — Optic Atrophy 1 discovered through SciDEX knowledge graph analysis: